Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease

Journal of Veterinary Internal Medicine

Volumn 24, Issue 2, 2010, Pages 331-341

  Bernay, F ^a   Bland, J M ^b   Haggstrom J ^c   Baduel, L ^a   Combes, B ^d   Lopez, A ^a   Kaltsatos, V ^a  

^a CEVA SANTÉ ANIMALE   (France)

^b UNIVERSITY OF YORK   (United Kingdom)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^d Stalphamis ^*  (France)

Author keywords

Canine; Clinical trial; Evidence based medicine; Heart failure

Indexed keywords

CARDIOTONIC AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; MALE; MITRAL VALVE REGURGITATION; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOTONIC AGENTS; DIGOXIN; DIURETICS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; MALE; MITRAL VALVE INSUFFICIENCY; PROPORTIONAL HAZARDS MODELS; SPIRONOLACTONE;

ANIMALIA; CANIS FAMILIARIS;

EID: 77649141892     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0467.x     Document Type: Article

References (34)

1. Tan LB, Schlosshan D, Barker D. Fiftieth anniversary of aldosterone: From discovery to cardiovascular therapy. Int J Cardiol 2004;96:321-333.
2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
3. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002;103:425-431.
4. Pu Q, Neves MF, Virdis A, et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.
5. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-677.
6. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-575.
7. Pitt B. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 1995;9:145-149.
8. Häggström J, Hansson K, Karlberg BE, et al. Effects of longterm treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996;57:1645-1652.
9. Kvart C, Häggström J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:80-88.
10. Atkins CE, Keene W, Brown WA, et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007;231:1061-1069.
11. Hori Y, Katou A, Tsubaki M, et al. Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs. Am J Vet Res 2008;69:1664-1669.
12. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62:723-731.
13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med 1999;341:709-717.
14. US Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine. Good Clinical Practices, VICH GL9 final guidance, 2001.
15. Chetboul V, Pouchelon JL, Bureau-Amaglio S, et al. Echocardiographie et echo-doppler du chien et du chat, Chapter 3, 1st ed. Masson: Paris; 1999:100-118.
16. Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194-199.
17. Elliot J, Guyonnet J, Kaltsatos V. Experimental studies of the pharmacology of spironolactone in dogs. Proceedings of 18th ECVIM Congress, Ghent, 2008.
18. Fox PR, Sisson D, Moise NS. Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, 2nd ed. Philadelphia, PA: WB Saunders; 1999:883-902.
19. Montori VM, Gordon HG. Intention-to-treat principle. Can Med Assoc J 2001;165:1339-1341.
20. Haggstrom J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The Quest study. J Vet Intern Med 2008;1-12.
21. The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:7-18.
22. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc 1998;213:1573-1577.
23. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-510.
24. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol 2002;161:1773-1781.
25. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-1800.
26. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-1376.
27. Shieh FK, Kotlyar E, Sam F. Aldosterone and cardiovascular remodelling: Focus on myocardial failure. J Renin Angiotensin Aldosterone Syst 2004;5:3-13.
28. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extra-cellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation 2000;102:2700-2706.
29. Dell Italia LJ, Balcells E, Meng QC, et al. Volume-overload cardiac hyperthrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol 1997;273:H961-H970.
30. Falk T, Jönsson L, Olsen LH, et al. Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous mitral valve disease. Cardiovasc Pathol 2006;15:185-193.
31. Falk T, Jönsson L, Olsen LH, et al. Correlation of cardiac pathology and clinical findings in dogs with naturally occurring congestive heart failure. Proceedings of 17th Annual ECVIM Congress, Budapest, 2007.
32. Yang S, Han W, Zhou H, et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J 2008;121:38-42.
33. Suzuki G, Morita H, Mishima T, et al. Effects of a long-term monotherapy with Eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodelling in dogs with heart failure. Circulation 2002;106:2967-2972.
34. Fuentes VL. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract 2004;34:1145-1155.